Lopinavir/ritonavir + tenofovir Dual Therapy versus Lopinavir/ritonavir-Based Triple Therapy in HIV-Infected Antiretroviral Naïve Subjects: The Kalead Study

Mari Pinola^1*, Adriano Lazzarin², Andrea Antinori³, Giampiero Carosi⁴, Giovanni Di Perri⁵, Mauro Moroni⁶, Vincenzo Vullo⁷, Giuseppe Pastore⁸, Michael Norton⁹ and Umberto Di Luzio Paparatti¹

¹Abbott Italy Medical Dept., Campoverde (LT), Italy, E-mail: adriano.lazzarin@raffaele.it

²Division of Infectious Diseases, IRCCS San Raffaele, Milan, Italy, E-mail: adriano.lazzarin@raffaele.it

³Clinical Department, National Institute of Infectious Diseases, Rome, Italy, E-mail: adriano.lazzarin@raffaele.it

⁴Institute of Infectious and Tropical Diseases, University of Brescia, Italy, E-mail: adriano.lazzarin@raffaele.it

⁵Institute of Infectious Diseases, University of Turin, Italy, E-mail: adriano.lazzarin@raffaele.it

⁶Institute of Infectious and Tropical Diseases, University of Milan, Italy, E-mail: adriano.lazzarin@raffaele.it

⁷1^st Division of Infectious and Tropical Diseases, University ‘La Sapienza’, Rome, Italy, E-mail: adriano.lazzarin@raffaele.it

⁸Unit of Infectious Diseases, Policlinico Consorziale Hospital, Bari, Italy, E-mail: adriano.lazzarin@raffaele.it

⁹Abbott Laboratories, North Chicago (IL), United States, E-mail: adriano.lazzarin@raffaele.it

^*Corresponding Author: Mari Pinola, Medical Department Abbott Italy, Via Pontina Km 52 – 04011 Campoverde (LT), Italy, Tel: +39 06 92 892 3075, Fax: 39 06 92 907 2649 Email: